(Q34506784)

2 August 2017

1 reference

title

Current medical therapies for patients with peripheral arterial disease: a critical review (English)

1 reference

2 August 2017

0 references

Judith G. Regensteiner

series ordinal

1

object named as

Judith G Regensteiner

1 reference

2 August 2017

2

William R Hiatt

1 reference

PubMed ID

11812407

2 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

American Journal of Medicine

2 August 2017

1 reference

2 August 2017

112

1 reference

2 August 2017

1

1 reference

2 August 2017

49-57

1 reference

The prevalence of peripheral arterial disease in a defined population

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Update on Some Epidemiologic Features of Intermittent Claudication: The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Mortality over a period of 10 years in patients with peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Mortality over four years in SHEP participants with a low ankle-arm index

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Ankle/arm pressure index in asymptomatic middle-aged males: an independent predictor of ten-year coronary heart disease mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Exercise training improves functional status in patients with peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Thrombotic thrombocytopenic purpura associated with clopidogrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Femoral atherosclerosis in an older British population: prevalence and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Conservative management of intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Diabetes and cardiovascular disease. The Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Long-term glycemic control relates to mortality in type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Intermittent claudication. A risk profile from The Framingham Heart Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Prevalence and correlates of lower extremity arterial disease in elderly women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Systolic hypertension in patients with arteriosclerosis obliterans of the lower limbs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Hyperhomocysteinemia: an independent risk factor for vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

The epidemiology of cardiovascular disease in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Oestrogen replacement therapy and cardiovascular disease in post-menopausal women. A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Effect of daily muscular exercise in patients with intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Exercise and intermittent claudication. Blood flow in the calf muscle during walking studied by the xenon-133 clearance method.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Metabolic Activity of Skeletal Muscle in Patients with Peripheral Arterial Insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Metabolism of [3H]benzo[a]pyrene by cultured human bronchus and cultured human pulmonary alveolar macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

A comparison of cilostazol and pentoxifylline for treating intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901034-8

10.1016/S0002-9343(01)01034-8

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11812407